Xbrane Biopharma AB (publ) (STO: XBRANE)

Market Cap	263.07M
Revenue (ttm)	199.81M
Net Income (ttm)	-370.56M
Shares Out	1.53B
EPS (ttm)	-0.44
PE Ratio	n/a
Forward PE	19.77
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,818,166
Open	0.181
Previous Close	0.181
Day's Range	0.176 - 0.185
52-Week Range	0.126 - 10.900
Beta	1.09
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 21, 2025

About Xbrane Biopharma AB

Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults. Its pre-clinical phase products include BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriati...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 93
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: XBRANE

Financial Performance

In 2023, Xbrane Biopharma AB's revenue was 238.73 million, an increase of 314.33% compared to the previous year's 57.62 million. Losses were -388.17 million, 125.0% more than in 2022.